0001725160-21-000008.txt : 20210106 0001725160-21-000008.hdr.sgml : 20210106 20210106202541 ACCESSION NUMBER: 0001725160-21-000008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210104 FILED AS OF DATE: 20210106 DATE AS OF CHANGE: 20210106 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: SUN ANTHONY Y CENTRAL INDEX KEY: 0001377952 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39263 FILM NUMBER: 21512596 MAIL ADDRESS: STREET 1: C/O AISLING CAPITAL STREET 2: 888 SEVENTH AVENUE, 30TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10106 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Zentalis Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001725160 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 BUSINESS PHONE: (212) 433-3791 MAIL ADDRESS: STREET 1: 530 SEVENTH AVENUE, SUITE 2201 CITY: NEW YORK STATE: NY ZIP: 10018 FORMER COMPANY: FORMER CONFORMED NAME: Zentalis Pharmaceuticals, LLC DATE OF NAME CHANGE: 20200107 FORMER COMPANY: FORMER CONFORMED NAME: Zeno Pharma, LLC DATE OF NAME CHANGE: 20171212 4 1 wf-form4_160998272301109.xml FORM 4 X0306 4 2021-01-04 0 0001725160 Zentalis Pharmaceuticals, Inc. ZNTL 0001377952 SUN ANTHONY Y C/O ZENTALIS PHARMACEUTICALS, INC. 530 SEVENTH AVENUE, SUITE 2201 NEW YORK NY 10018 1 1 0 0 President & CEO Common Stock 2020-11-22 5 G 0 E 213600 0 D 1804005 D Common Stock 2020-11-22 5 G 0 E 213600 0 A 213600 I See Footnote Common Stock 2021-01-04 4 S 0 5418 50.4668 D 1798587 D Common Stock 2021-01-04 4 S 0 3951 51.4056 D 1794636 D Common Stock 2021-01-04 4 S 0 10612 52.4741 D 1784024 D Common Stock 2021-01-04 4 S 0 6813 53.0632 D 1777211 D Common Stock 974302 I By Essex Group International, LLC Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.82 to $50.805. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.83 to $51.81. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.84 to $52.82. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.85 to $53.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. By: /s/ Melissa B. Epperly, Attorney-in-Fact for Anthony Y. Sun 2021-01-06